<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386734</url>
  </required_header>
  <id_info>
    <org_study_id>N/2016/72</org_study_id>
    <secondary_id>ENGOT-Cx4</secondary_id>
    <secondary_id>GINECO-CE106</secondary_id>
    <nct_id>NCT03386734</nct_id>
  </id_info>
  <brief_title>International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer</brief_title>
  <acronym>SENTICOLIII</acronym>
  <official_title>International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SENTICOL III is large prospective multicenter international randomized study designed to
      validate the Sentinel Lymph Node (SLN) mapping technique in early cervical cancer. This
      &quot;validation study&quot; will compare the outcome of patients with negative SLN (experimental arm)
      vs patients with negative SLN + Pelvic Lymph Node dissection (PLN)(reference arm).

      There will be a &quot;quality assurance&quot; program which will be developed in participating centers
      with detailed requirements in terms of surgeons' qualifications, pathology qualification, SLN
      ultrastaging, standardization of the procedure, etc. as well as respect of the &quot;safety
      algorithm&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Year 3</time_frame>
    <description>Composite outcome: the time interval between randomization and recurrence (local/distant) or second cancer or death (all causes), whichever occurs first.
This time interval will be analysed concomitantly with HR-QoL scores as a composite outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life (HR-QoL)</measure>
    <time_frame>Year 3</time_frame>
    <description>Composite outcome: significant deterioration will specifically be assessed through 3 targeted dimensions (pain score, global health score and physical functioning scores) in EORTC QLQ-C30 and QLQ-CX24 questionnaires.
These scores will be analysed concomitantly with DFS as a composite outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>SLN biopsy only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLN biopsy + PLN dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SLN biopsy only</intervention_name>
    <description>In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.</description>
    <arm_group_label>SLN biopsy only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SLN biopsy + PLN dissection</intervention_name>
    <description>In active comparator arm, SLN dissection + full lymphadenectomy will be performed.</description>
    <arm_group_label>SLN biopsy + PLN dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With squamous or adenocarcinoma of the cervix (proven by biopsy or cone biopsy),

          -  Stage Ia1 with lymphovascular emboli to IIa1 (clinical stage) of the 2009
             International Federation of Gynecology and Obstetrics (FIGO) classification,

          -  Maximum diameter ≤ 40 mm by clinical examination and magnetic resonance imaging (MRI),

          -  No suspicious node on pelvic and abdominal MRI (according to RECIST 1.1),

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2,

          -  Signed informed consent and ability to comply with follow-up,

          -  French subjects: in France, a subject will be eligible for inclusion in this study
             only if either affiliated to, or a beneficiary of, a social security category.

        Exclusion Criteria:

          -  Pregnancy,

          -  Previous pelvic or abdominal cancer,

          -  Previous chemotherapy and/or radiation therapy for the cervical cancer (previous
             brachytherapy is accepted),

          -  Proven allergy to blue dye, isotope or indocyanine green (ICG).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Lecuru, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie Mijonnet</last_name>
    <phone>0033142348323</phone>
    <email>smijonnet@arcagy.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Mouyabi</last_name>
    <phone>0033381218356</phone>
    <email>kmouyabi@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Félix Guyon</name>
      <address>
        <city>Saint-Denis</city>
        <state>La Réunion</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anca Paula Birsan Frances, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice Sergent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurène Lugans, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli-Ducos</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Richard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaele Fauvet, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand - Hôpital d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Leblanc, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Collinet, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Est - Hôpital Femme Mère Enfant</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gautier Chene, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aubert Agostini, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth Chereau-Ewald, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Lambaudie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse - Hôpital du Hasenrain</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramzi Kacem, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Jaffre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Koskas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Uzan, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice Lecuru, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emile Darai, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Golfier, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Poissy-Saint-Germain-en-Laye</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyrille Huchon, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cédric Nadeau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Graesslin, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erica Bentivegna, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

